{
  "meta": {
    "title": "Asthma_And_Hypersensitivity_Pneumonitis",
    "url": "https://brainandscalpel.vercel.app/asthma-and-hypersensitivity-pneumonitis-90c7b9d1.html",
    "scrapedAt": "2025-11-30T08:48:56.603Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Asthma </span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Congestive cardiac failure </span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Bronchogenic carcinoma</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Monophonic Rhonchi is seen in which of the following condition?</span></p>",
      "unique_key": "DT1295436",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295436,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Obstructive Lung Disease:</strong> Characterized by airway diseases, primarily affecting airflow.</li>\r\n<li><strong>Key PFT Measurement:</strong>\r\n<ul>\r\n<li><strong>FEV1/FVC &lt;70%</strong> confirms obstructive lung disease.</li>\r\n</ul>\r\n</li>\r\n<li><strong>TLC (Total Lung Capacity):</strong> Usually normal in obstructive diseases; reduced in restrictive diseases.</li>\r\n<li><strong>Diffusion Capacity (DLCO):</strong>\r\n<ul>\r\n<li><strong>Normal</strong> in asthma; decreased in COPD due to parenchymal involvement.</li>\r\n</ul>\r\n</li>\r\n<li><strong>PFT Patterns:</strong>\r\n<ul>\r\n<li><strong>Obstructive:</strong> Low FEV1/FVC ratio (&lt;70%).</li>\r\n<li><strong>Restrictive:</strong> Normal or increased FEV1/FVC ratio (&gt;70%).</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) Total lung capacity &lt;80%:</strong> Not specific to obstructive disease, as it can occur in restrictive diseases.</li>\r\n<li><strong>C) Reduced diffusion capacity:</strong> Indicates parenchymal disease, not specific to obstruction.</li>\r\n<li><strong>D) All of the above:</strong> Incorrect, as not all options indicate obstructive disease.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>FEV1/FVC ratio &lt;70%</strong> is definitive for diagnosing <strong>obstructive lung disease</strong>.</li>\r\n<li>Understanding the distinction between obstructive and restrictive patterns is crucial for proper diagnosis and management.</li>\r\n<li>The measurement of <strong>DLCO</strong> provides additional insights but is not solely indicative of obstructive lung disease.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Total lung capacity <80%</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">FEV1/FVC<70%</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduced diffusion capacity for carbon monoxide.</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following pattern of pulmonary function test confirms diagnosis of obstructive lung disease?</span></p>",
      "unique_key": "DT1295734",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295734,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Obstructive Lung Disease:</strong> Primarily caused by <strong>airway diseases</strong>, affecting airflow.</li>\r\n<li><strong>Key PFT Indicator:</strong>\r\n<ul>\r\n<li><strong>FEV1/FVC &lt;70%</strong> is the hallmark for confirming obstructive lung disease.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Comparison of Lung Function Tests:</strong>\r\n<ul>\r\n<li><strong>FEV1/FVC Ratio:</strong>\r\n<ul>\r\n<li><strong>Obstructive:</strong> &lt;70% (indicates significant obstruction).</li>\r\n<li><strong>Restrictive:</strong> &gt;70% (airflow is preserved despite reduced lung volumes).</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li><strong>Diffusion Capacity (DLCO):</strong>\r\n<ul>\r\n<li><strong>Normal</strong> in asthma; may be <strong>decreased</strong> in COPD due to parenchymal involvement.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Total Lung Capacity (TLC):</strong>\r\n<ul>\r\n<li>Usually <strong>normal</strong> in obstructive lung disease, may be decreased in restrictive lung diseases.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250109c8a718c8-4655-488c-a76b-f5572383c1c5.jpg\">\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) Total lung capacity &lt;80%:</strong> This criterion does not specifically indicate obstructive disease; it can occur in restrictive lung diseases.</li>\r\n<li><strong>C) Reduced diffusion capacity for carbon monoxide:</strong> Primarily indicates parenchymal involvement, not solely obstructive disease.</li>\r\n<li><strong>D) All of the above:</strong> Incorrect, as only the FEV1/FVC ratio is definitive for obstructive lung disease.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>A <strong>FEV1/FVC ratio &lt;70%</strong> is essential for diagnosing <strong>obstructive lung disease</strong>.</li>\r\n<li>Understanding the differences between obstructive and restrictive patterns is crucial for accurate diagnosis.</li>\r\n<li>The <strong>diffusion capacity (DLCO)</strong> provides additional information but is not specific to obstruction.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic obstructive airway disease </span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary fibrosis </span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Fixed Intrathoracic obstruction </span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Fixed Extra thoracic obstruction </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The flow volume curve which is shown below is seen in which of the following diseases?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501091606b004-1e33-416b-95b7-c97568462a6a.jpg\"></span></p>",
      "unique_key": "DT1295735",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295735,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Flow Volume Curve Characteristics:</strong>\r\n<ul>\r\n<li>The curve displays <strong>expiratory and inspiratory loops</strong>, with the <strong>expiratory loop scooped out</strong> in cases of airway disease.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Chronic Obstructive Pulmonary Disease (COPD):</strong>\r\n<ul>\r\n<li><strong>Scooping of the curve</strong> occurs due to:\r\n<ul>\r\n<li><strong>Loss of elastic recoil</strong> in lung parenchyma.</li>\r\n<li><strong>Increased airway resistance</strong> at lower lung volumes, leading to significant airflow reduction.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li><strong>Comparison with Other Conditions:</strong>\r\n<ul>\r\n<li><strong>Pulmonary Fibrosis:</strong> Shows a restrictive pattern with a reduced overall lung volume but a normal flow rate, not scooped.</li>\r\n<li><strong>Fixed Intrathoracic Obstruction:</strong> Presents with a flattened curve during expiration, affecting peak flow rates but not producing a classic scoop.</li>\r\n<li><strong>Fixed Extrathoracic Obstruction:</strong> Typically leads to a similar flat expiratory loop, not characteristic of the scooped appearance seen in COPD.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p>Also try to remember the airflow curves of different disease:</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2024010922d87845-52e2-465b-83ab-af173eba9a1f.jpg\">\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>B) Pulmonary fibrosis:</strong> This condition shows a restrictive pattern, leading to a normal shape of the flow-volume curve, not scooped.</li>\r\n<li><strong>C) Fixed intrathoracic obstruction:</strong> This results in a flattened expiratory curve, unlike the characteristic scoop of COPD.</li>\r\n<li><strong>D) Fixed extrathoracic obstruction:</strong> Similar to intrathoracic obstruction, this does not display the characteristic scooping seen in COPD.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>The <strong>scooped appearance</strong> of the flow-volume curve is a hallmark of <strong>chronic obstructive airway disease (COPD)</strong>.</li>\r\n<li>Understanding different <strong>flow volume curves</strong> aids in differentiating between obstructive and restrictive lung diseases.</li>\r\n<li>Recognizing these patterns is crucial for accurate diagnosis and management in pulmonary medicine.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Airway inflammation </span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Structural changes</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Airway reversibility </span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following clinical/laboratory feature differentiates between Asthma and Chronic obstructive airway disease?</span></p>",
      "unique_key": "DT1295736",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295736,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Airway Reversibility:</strong>\r\n<ul>\r\n<li><strong>Asthma</strong> is characterized by <strong>airway reversibility</strong>, which is the key differentiating feature from <strong>Chronic Obstructive Pulmonary Disease (COPD)</strong>.</li>\r\n<li>Reversibility is defined as:\r\n<ul>\r\n<li>A <strong>&ge;12% increase in FEV1</strong> and an <strong>absolute increase of &ge;200 mL</strong> at least <strong>15 minutes after &beta;2-agonist administration</strong> or after several weeks of corticosteroid therapy.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Airway Inflammation:</strong>\r\n<ul>\r\n<li>Both conditions exhibit airway inflammation, but the types and patterns differ; this feature does not distinctly separate asthma from COPD.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Structural Changes:</strong>\r\n<ul>\r\n<li>Both asthma and COPD can exhibit structural changes in the airways over time, particularly with chronic inflammation; hence, this is not a differentiating factor.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) Airway inflammation:</strong> Present in both asthma and COPD, hence not a distinguishing feature.</li>\r\n<li><strong>B) Structural changes:</strong> While present in both conditions, these changes do not differentiate them.</li>\r\n<li><strong>D) All of the above:</strong> Incorrect as only airway reversibility is a distinguishing feature.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Airway reversibility</strong> is the hallmark of <strong>asthma</strong>, setting it apart from COPD.</li>\r\n<li>Recognizing the diagnostic criteria for asthma is crucial in clinical practice.</li>\r\n<li>Effective management relies on understanding these differences to tailor treatment strategies.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Type 2 inflammation</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Type 1 inflammation</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Type 3 inflammation </span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Type 4 inflammation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The airway Inflammation in asthma occurs by which of the following immune response pathway?</span></p>",
      "unique_key": "DT1295737",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295737,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Type 2 Inflammation:</strong>\r\n<ul>\r\n<li>The airway inflammation in <strong>asthma</strong> is primarily driven by the <strong>Type 2 immune response pathway</strong>.</li>\r\n<li>Key components involved in this pathway include:\r\n<ul>\r\n<li><strong>Interleukins (IL-4, IL-5, IL-13):</strong> These cytokines play crucial roles in promoting eosinophilic inflammation and IgE production.</li>\r\n<li><strong>Eosinophils:</strong> These cells are central to the inflammatory process in asthma, contributing to tissue damage and bronchoconstriction.</li>\r\n<li><strong>Mast cells and Basophils:</strong> These cells release mediators that lead to bronchoconstriction and further inflammation.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Coexistence of Non-Type 2 Processes:</strong>\r\n<ul>\r\n<li>Although Type 2 pathways are dominant, <strong>non-Type 2 processes</strong> like neutrophil inflammation may also be present, especially in severe asthma.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>B) Type 1 inflammation:</strong> Primarily associated with viral infections and intracellular pathogens; not the main pathway in asthma.</li>\r\n<li><strong>C) Type 3 inflammation:</strong> Involves immune complex-mediated responses; not typically implicated in asthma.</li>\r\n<li><strong>D) Type 4 inflammation:</strong> Characterized by delayed-type hypersensitivity responses; more relevant in conditions like contact dermatitis, not asthma.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Asthma</strong> is predominantly driven by <strong>Type 2 inflammation</strong>, highlighting the role of <strong>IL-4, IL-5, and IL-13</strong>.</li>\r\n<li>Understanding these pathways is essential for targeted therapies in asthma management.</li>\r\n<li>Eosinophils and mast cells are key players in the inflammatory process, leading to the characteristic symptoms of asthma.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 41,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">B-blockers </span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin </span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">ACE inhibitors </span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drug is not associated with exacerbation or acute worsening of asthma?</span></p>",
      "unique_key": "DT1295738",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295738,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Exacerbation of Asthma:</strong>\r\n<ul>\r\n<li><strong>B-blockers:</strong> Can cause bronchospasm by blocking &beta;2-adrenergic receptors, leading to acute worsening of asthma symptoms.</li>\r\n<li><strong>Aspirin:</strong> Known to trigger <strong>aspirin-induced asthma</strong>, exacerbating symptoms due to increased leukotriene production.</li>\r\n<li><strong>ACE inhibitors:</strong> Associated with cough and potential bronchoconstriction, which can worsen asthma.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Triggers for Acute Exacerbation of Bronchial Asthma:</strong>\r\n<ul>\r\n<li><strong>Allergens:</strong> Common triggers include pollen, dust mites, and pet dander.</li>\r\n<li><strong>Irritants:</strong> Tobacco smoke, strong odors, and pollution can provoke symptoms.</li>\r\n<li><strong>Viral Infections:</strong> Respiratory viruses often lead to asthma exacerbations.</li>\r\n<li><strong>Exercise or Cold Air:</strong> Physical activity, especially in cold or dry air, can trigger symptoms.</li>\r\n<li><strong>Drugs:</strong> As mentioned, various medications can lead to exacerbations.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250313a5e475e5-9123-4cb1-bd92-45cd08487b9f.jpg\">\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) B-blockers:</strong> Directly exacerbate asthma due to &beta;-blockade.</li>\r\n<li><strong>B) Aspirin:</strong> Commonly triggers worsening symptoms in asthmatics.</li>\r\n<li><strong>C) ACE inhibitors:</strong> Can lead to cough and bronchospasm in susceptible individuals.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>All listed drugs (B-blockers, Aspirin, ACE inhibitors)</strong> are associated with exacerbation of asthma, highlighting the need for caution in asthmatic patients.</li>\r\n<li>Understanding the impact of medications is crucial for effective asthma management and avoiding potential triggers.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Chest X-ray </span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">HRCT chest </span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Methacholine provocation test </span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary function test with reversibility </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 15 years old male presents with history of chronic cough, episodic breathlessness and wheeze. Which of the following investigations will confirm the diagnosis of bronchial asthma?</span></p>",
      "unique_key": "DT1295739",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295739,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Diagnosis of Bronchial Asthma:</strong>\r\n<ul>\r\n<li><strong>History:</strong> Key symptoms include chronic cough, episodic breathlessness, and wheezing, often with diurnal and seasonal variations.</li>\r\n<li><strong>Examination:</strong> Look for <strong>polyphonic wheeze</strong>; during an acute attack, wheeze may be absent due to respiratory fatigue.</li>\r\n<li><strong>Pulmonary Function Test (PFT):</strong>\r\n<ul>\r\n<li><strong>Key Features:</strong>\r\n<ul>\r\n<li><strong>FEV1 and FVC</strong> are reduced, leading to a decreased <strong>FEV1/FVC ratio</strong>.</li>\r\n<li>The flow-volume loop may exhibit characteristic <strong>scalloping</strong>.</li>\r\n<li><strong>Reversibility Testing:</strong> Confirmed by a &ge;12% increase in FEV1 and an absolute increase of &ge;200 mL after a &beta;2-agonist administration, indicating reversible airway obstruction.</li>\r\n<li><strong>Diurnal Peak Flow Variability:</strong> Variability of &gt;20% suggests reversible airways disease.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Tests:</strong>\r\n<ul>\r\n<li><strong>Chest X-ray:</strong> May show hyperinflation but does not confirm asthma.</li>\r\n<li><strong>HRCT Chest:</strong> Useful for assessing structural lung disease but not diagnostic for asthma.</li>\r\n<li><strong>Methacholine Provocation Test:</strong> Assesses airway hyperresponsiveness but is not definitive for asthma diagnosis.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) Chest X-ray:</strong> Not diagnostic; can help rule out other conditions.</li>\r\n<li><strong>B) HRCT Chest:</strong> Evaluates lung anatomy but does not confirm asthma.</li>\r\n<li><strong>C) Methacholine Provocation Test:</strong> Indicates airway hyperreactivity but is not a confirmatory test for asthma.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Pulmonary function test with reversibility</strong> is the gold standard for diagnosing bronchial asthma, confirming airway obstruction and its reversibility.</li>\r\n<li>Recognizing clinical history and symptoms is crucial, but objective testing solidifies the diagnosis and guides effective management.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Indacaterol </span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Formoterol </span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Salmeterol </span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Albuterol </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a short acting B-agonist used for management of asthma?</span></p>",
      "unique_key": "DT1295740",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295740,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Bronchodilators Overview:</strong>\r\n<ul>\r\n<li><strong>Classes:</strong> Include &beta;-agonists, anticholinergics, and theophylline.</li>\r\n<li><strong>Function:</strong> Relax airway smooth muscle, improving airflow in asthma.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Short-acting &beta;-agonists (SABAs):</strong>\r\n<ul>\r\n<li><strong>Examples:</strong>\r\n<ul>\r\n<li><strong>Albuterol</strong>: A primary choice for quick relief in asthma management.</li>\r\n<li><strong>Formoterol</strong>: Although primarily considered a long-acting &beta;-agonist (LABA), it has some quick-onset properties but is not typically classified as a SABA.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Long-acting &beta;-agonists (LABAs):</strong> Include Salmeterol and Formoterol.</li>\r\n<li><strong>Ultra-long acting &beta;-agonists:</strong> Include Indacaterol and others.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Side Effects of &beta;-agonists:</strong>\r\n<ul>\r\n<li>Common adverse effects include <strong>tremors, tachycardia, palpitations, hypertension,</strong> and <strong>hypokalemia</strong> at high doses.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) Indacaterol:</strong> An ultra-long-acting &beta;-agonist, not suitable for acute asthma management.</li>\r\n<li><strong>B) Formoterol:</strong> While it can be used for quick relief, it is primarily classified as a long-acting &beta;-agonist.</li>\r\n<li><strong>C) Salmeterol:</strong> A long-acting &beta;-agonist, effective for maintenance therapy but not for acute relief.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Albuterol</strong> is the primary <strong>short-acting &beta;-agonist (SABA)</strong> for immediate relief in asthma management.</li>\r\n<li><strong>Understanding the classifications of bronchodilators</strong> is essential for appropriate asthma treatment, ensuring effective management of acute and chronic symptoms.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 74,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhalational corticosteroids </span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">B-agonists </span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-Muscarinic agents </span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drug is associated with decreased mortality in Asthma?</span></p>",
      "unique_key": "DT1295741",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295741,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Inhalational Corticosteroids (ICS):</strong>\r\n<ul>\r\n<li><strong>Decreased Mortality:</strong> ICS are the only drug class shown to reduce mortality in asthma patients.</li>\r\n<li><strong>Mechanism of Action:</strong>\r\n<ul>\r\n<li><strong>Reduce Airway Hyperresponsiveness:</strong> They stabilize the airway and decrease inflammation.</li>\r\n<li><strong>Improve Airway Function:</strong> Enhance lung function and prevent exacerbations.</li>\r\n<li><strong>Minimize Systemic Toxicity:</strong> By using inhalational delivery, ICS reduces side effects compared to systemic corticosteroids.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li><strong>Leukotriene Modifiers:</strong>\r\n<ul>\r\n<li><strong>Function:</strong> Improve airway function and reduce exacerbations.</li>\r\n<li><strong>Examples:</strong>\r\n<ul>\r\n<li><strong>Montelukast</strong> and <strong>Zafirlukast:</strong> Leukotriene receptor antagonists.</li>\r\n<li><strong>Zileuton:</strong> An inhibitor of 5-lipoxygenase, which reduces leukotriene synthesis.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>B) &beta;-agonists:</strong> Effective for symptom relief but do not reduce mortality.</li>\r\n<li><strong>C) Anti-muscarinic agents:</strong> Primarily used for symptomatic relief and have not demonstrated mortality benefits.</li>\r\n<li><strong>D) All of the above:</strong> Incorrect, as only inhalational corticosteroids are associated with decreased mortality.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Inhalational corticosteroids (ICS)</strong> are essential in asthma management, significantly lowering the risk of mortality.</li>\r\n<li>Understanding the role of different medication classes helps in optimizing asthma treatment strategies and improving patient outcomes.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 84,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Mepolizumab</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Reslizumab </span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Benralizumab </span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is anti-IL-5 drug used in management of asthma? </span></p>",
      "unique_key": "DT1295742",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295742,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\n<li><strong>Anti-IL-5 Therapy:</strong>\n<ul>\n<li><strong>Purpose:</strong> Used for asthma patients who remain symptomatic despite moderate to high doses of inhalational corticosteroids.</li>\n<li><strong>Effectiveness:</strong> Most beneficial when eosinophil counts are &gt;300/uL, targeting eosinophilic inflammation in asthma.</li>\n</ul>\n</li>\n<li><strong>Drugs Included:</strong>\n<ul>\n<li><strong>Mepolizumab:</strong> Anti-IL-5 monoclonal antibody.</li>\n<li><strong>Reslizumab:</strong> Another anti-IL-5 monoclonal antibody.</li>\n<li><strong>Benralizumab:</strong> An IL-5 receptor antagonist, blocking the action of IL-5 on its receptor.</li>\n</ul>\n</li>\n<li><strong>Related Therapies:</strong>\n<ul>\n<li><strong>Anti-IgE Therapy:</strong> Omalizumab, used to inhibit IgE in allergic asthma.</li>\n<li><strong>Anti-IL4/13 Therapy:</strong> Dupilumab, targeting IL-4 and IL-13 pathways in asthma.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Why Not Others:</strong></p>\n<ul>\n<li><strong>A) Mepolizumab:</strong> Correctly identified as an anti-IL-5 but not solely representative of the class.</li>\n<li><strong>B) Reslizumab:</strong> Also an anti-IL-5 drug, thus cannot be excluded.</li>\n<li><strong>C) Benralizumab:</strong> This drug is correctly classified as an anti-IL-5 but specifically as a receptor antagonist.</li>\n</ul>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li><strong>All listed drugs (Mepolizumab, Reslizumab, and Benralizumab)</strong> are effective anti-IL-5 therapies for managing severe asthma.</li>\n<li>Recognizing and remembering the various biologics used in asthma treatment is crucial for optimal patient management.</li>\n</ul>",
      "correct_choice_id": 94,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Urgently start on B-agonist Nebulisation.</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">IV corticosteroids </span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">IM magnesium</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">IV Theophylline </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A diagnosed case of bronchial asthma reports to medical emergency with severe respiratory distress following exposure to allergen. Sp02 is 80% and Respiratory rate is 35/min. He is following commands What is the first step in the management of this patient?</span></p>",
      "unique_key": "DT1295743",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295743,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Severe Respiratory Distress:</strong>\r\n<ul>\r\n<li><strong>Symptoms:</strong> Severe tachypnea and Sp02 &lt; 92% indicate acute severe asthma.</li>\r\n<li><strong>Immediate Action:</strong> The priority is to relieve bronchospasm and improve oxygenation.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Management Steps:</strong>\r\n<ul>\r\n<li><strong>First Line:</strong> <strong>Nebulization with inhaled B-agonist</strong> (e.g., Albuterol) is essential. Administer every 20 minutes to rapidly open airways. Supplemental oxygen should be provided to improve oxygen saturation.</li>\r\n<li><strong>Second Line:</strong> If there is no response after 1-2 hours, IV corticosteroids should be initiated to reduce inflammation.</li>\r\n<li><strong>Third Line:</strong> Noninvasive ventilation may be required, with mechanical ventilation considered if the patient does not improve.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>B) IV Corticosteroids:</strong> While important, they are not the first step in acute management. They take time to exert effects.</li>\r\n<li><strong>C) IM Magnesium:</strong> Used as a second or third-line option but not first-line management.</li>\r\n<li><strong>D) IV Theophylline:</strong> Less commonly used in acute settings and not the immediate treatment of choice for severe distress.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>First step:</strong> <strong>Nebulization with B-agonist</strong> is crucial in managing acute severe asthma with low Sp02.</li>\r\n<li>Rapid intervention is key to improving airway obstruction and oxygenation, emphasizing the need for immediate bronchodilation.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Diisocyanates </span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Aromatic amines </span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Acid Anhydrides </span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following occupational exposure is associated with asthma?</span></p>",
      "unique_key": "DT1295744",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295744,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Occupational Asthma:</strong>\r\n<ul>\r\n<li><strong>Causes:</strong> Occupational asthma can arise from exposure to various agents in the workplace, including:\r\n<ul>\r\n<li><strong>Diisocyanates:</strong> Commonly found in polyurethane production, known to trigger asthma symptoms.</li>\r\n<li><strong>Aromatic Amines:</strong> Used in dye and chemical manufacturing, associated with respiratory issues.</li>\r\n<li><strong>Acid Anhydrides:</strong> Found in epoxy and resin manufacturing, they can also lead to asthma-like symptoms.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Elderly Onset Asthma:</strong>\r\n<ul>\r\n<li><strong>Not limited to children:</strong> While asthma is often considered a pediatric disease, it can develop in older adults due to occupational exposures or smoking.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) Diisocyanates:</strong> Though they are a known trigger, they alone do not encompass all occupational exposures related to asthma.</li>\r\n<li><strong>B) Aromatic Amines:</strong> Similarly, they are a contributor but not the only exposure.</li>\r\n<li><strong>C) Acid Anhydrides:</strong> Also a trigger, but the question asks for the most comprehensive answer.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Occupational exposures,</strong> including <strong>diisocyanates, aromatic amines, and acid anhydrides,</strong> are all associated with asthma.</li>\r\n<li><strong>Elderly onset asthma</strong> highlights the importance of considering occupational exposures across all age groups, particularly in those with a history of environmental exposure.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 114,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Short acting B agonist as and when required </span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-muscarinic agent as and when required </span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhalational corticosteroids as and when required </span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral Leukotriene antagonist </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">As per the current guidelines what is the therapy for intermittent asthma?</span></p>",
      "unique_key": "DT1295745",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295745,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Therapy for Intermittent Asthma:</strong>\r\n<ul>\r\n<li><strong>Short-acting &beta;-agonists (SABAs):</strong> These are the preferred treatment for patients with intermittent asthma to provide <strong>symptomatic relief</strong> as needed. Examples include albuterol and levalbuterol.</li>\r\n<li><strong>Inhalational corticosteroids (ICS):</strong> Not used alone for intermittent asthma; they are reserved for more persistent symptoms.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Guideline Approach:</strong>\r\n<ul>\r\n<li><strong>Stepwise Management:</strong>\r\n<ul>\r\n<li><strong>Step 1:</strong> Use <strong>SABA</strong> as needed or <strong>ICS (low dose) + Formoterol</strong> for better control.</li>\r\n<li><strong>Step 2:</strong> Add low-dose ICS to SABA if symptoms are frequent.</li>\r\n<li><strong>Step 3:</strong> Increase to medium-dose ICS if further control is needed.</li>\r\n<li><strong>Step 4:</strong> High-dose ICS may be required for persistent symptoms.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>B) Anti-muscarinic agent as and when required:</strong> These are not first-line treatments for intermittent asthma.</li>\r\n<li><strong>C) Inhalational corticosteroids as and when required:</strong> ICS is not indicated for intermittent asthma without the presence of persistent symptoms.</li>\r\n<li><strong>D) Oral leukotriene antagonist:</strong> These are not typically used for intermittent asthma management.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>SABAs</strong> are the primary therapy for <strong>intermittent asthma</strong></li>\r\n<li><strong>ICS</strong> and other agents are reserved for <strong>persistent symptoms</strong>, emphasizing the importance of a stepwise approach in asthma management.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Viral pneumonia </span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute hypersensitivity pneumonitis </span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic obstructive pulmonary disease </span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Exacerbation of asthma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A farmer, after working in grain storage, develops fever, chills and malaise with mild dyspnoea. He has history of similar episodes in the past and symptoms develop only after prolonged working in grain storage. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295746",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295746,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Acute Hypersensitivity Pneumonitis (HP)</strong> is an <strong>allergic reaction</strong> triggered by <strong>inhalation of organic dust</strong> such as moldy hay or grain dust (common in farmers).\r\n<ul>\r\n<li>Symptoms include <strong>fever, chills, malaise</strong>, and <strong>dyspnoea</strong> following <strong>re-exposure</strong> to the allergen.</li>\r\n<li><strong>History of episodes</strong> after exposure supports the diagnosis.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) Viral pneumonia:</strong> Fever and chills are present, but <strong>dyspnoea with allergen exposure</strong> and <strong>recurrent episodes</strong> are not typical for viral pneumonia.</li>\r\n<li><strong>C) Chronic obstructive pulmonary disease (COPD):</strong> Symptoms in COPD are persistent, not episodic or linked to <strong>specific allergen exposure</strong>.</li>\r\n<li><strong>D) Exacerbation of asthma:</strong> Asthma exacerbations are more likely to involve <strong>multiple allergens</strong> and <strong>airway hyperresponsiveness</strong>, unlike the single allergen trigger seen here.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Hypersensitivity pneumonitis</strong> is characterized by <strong>episodic respiratory symptoms</strong> triggered by specific <strong>environmental allergens</strong> such as grain dust.</li>\r\n<li>Distinct from <strong>COPD</strong> and <strong>asthma</strong>, where symptoms persist or are triggered by multiple allergens.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Type I</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Type II</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Type III</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">None </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Hypersensitivity pneumonitis is a which form/type of immune hypersensitivity reaction?</span></p>",
      "unique_key": "DT1295747",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295747,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Hypersensitivity pneumonitis (HP)</strong> is primarily a <strong>Type III hypersensitivity reaction</strong>, involving <strong>immune complex deposition</strong> triggered by <strong>allergen-specific IgG antibodies</strong>.</li>\r\n<li>As HP progresses, there may also be a component of <strong>Type IV hypersensitivity</strong> due to delayed cellular immune responses.</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) Type I:</strong> Involves <strong>IgE-mediated</strong> reactions, typical in <strong>asthma</strong> or <strong>anaphylaxis</strong>, not HP.</li>\r\n<li><strong>B) Type II:</strong> Involves <strong>antibody-mediated</strong> cytotoxicity (e.g., autoimmune hemolytic anemia), which is unrelated to HP.</li>\r\n<li><strong>D) None:</strong> HP is clearly linked to <strong>Type III</strong></li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Hypersensitivity pneumonitis</strong> is an interstitial lung disease driven by <strong>Type III immune reactions</strong>, progressing to involve <strong>Type IV</strong></li>\r\n</ul>\r\n ",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Caseating granuloma </span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">BAL Neutrophilia </span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">CD4/CD8 Lymphocyte ratio<1 </span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is feature of Hypersensitivity pneumonitis?</span></p>",
      "unique_key": "DT1295748",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295748,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Hypersensitivity pneumonitis (HP)</strong> is primarily a <strong>Type III hypersensitivity reaction</strong>, involving <strong>immune complex deposition</strong> triggered by <strong>allergen-specific IgG antibodies</strong>.</li>\r\n<li>As HP progresses, there may also be a component of <strong>Type IV hypersensitivity</strong> due to delayed cellular immune responses.</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) Type I:</strong> Involves <strong>IgE-mediated</strong> reactions, typical in <strong>asthma</strong> or <strong>anaphylaxis</strong>, not HP.</li>\r\n<li><strong>B) Type II:</strong> Involves <strong>antibody-mediated</strong> cytotoxicity (e.g., autoimmune hemolytic anemia), which is unrelated to HP.</li>\r\n<li><strong>D) None:</strong> HP is clearly linked to <strong>Type III</strong></li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Hypersensitivity pneumonitis</strong> is an interstitial lung disease driven by <strong>Type III immune reactions</strong>, progressing to involve <strong>Type IV</strong></li>\r\n</ul>\r\n ",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug induced asthma</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Allergic bronchopulmonary aspergillosis </span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Occupational asthma </span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 30 years old female presents with chronic cough, mucoid expectoration, seasonal variation in symptoms and episodic breathlessness. Pulmonary function test confirms the diagnosis of bronchial asthma. Serum IgE is more than 1500 IU/ml. which of the following must be considered as possible diagnosis in this case?</span></p>",
      "unique_key": "DT1295749",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295749,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Key Features:</strong>\r\n<ul>\r\n<li><strong>History:</strong> Chronic cough, mucoid expectoration, seasonal symptom variation, and episodic breathlessness are classic indicators of asthma.</li>\r\n<li><strong>Serum IgE Levels:</strong> An elevated serum IgE (&gt;1500 IU/ml) suggests a significant allergic component.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Allergic Bronchopulmonary Aspergillosis (ABPA):</strong>\r\n<ul>\r\n<li><strong>Association:</strong> Characterized by asthma-like symptoms, <strong>central bronchiectasis</strong>, and notably high serum IgE levels (typically &gt;1000 IU/ml).</li>\r\n<li><strong>Importance of Diagnosis:</strong> ABPA should be suspected in asthmatic patients with extremely high serum IgE, as it indicates an immune response to the <em>Aspergillus</em></li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Conditions:</strong>\r\n<ul>\r\n<li><strong>A) Drug-induced asthma:</strong> Drugs like &beta;-blockers, aspirin, and NSAIDs can exacerbate asthma but do not typically cause significant increases in serum IgE.</li>\r\n<li><strong>C) Occupational asthma:</strong> While it can contribute to asthma symptoms, it does not correlate with elevated serum IgE levels in the same manner as ABPA.</li>\r\n<li><strong>D) All of the above:</strong> Incorrect since only ABPA is strongly indicated by high IgE levels.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A) Drug-induced asthma:</strong> Does not lead to significant increases in serum IgE; rather, it exacerbates existing asthma.</li>\r\n<li><strong>C) Occupational asthma:</strong> Primarily linked to workplace exposures but not characterized by high serum IgE levels.</li>\r\n<li><strong>D) All of the above:</strong> Misleading, as only ABPA correlates with the presented high serum IgE levels.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>High serum IgE levels (&gt;1500 IU/ml)</strong> in an asthmatic patient strongly suggest the possibility of <strong>Allergic Bronchopulmonary Aspergillosis (ABPA)</strong>.</li>\r\n<li>Identifying ABPA is crucial for managing patients with asthma, especially when serum IgE levels are significantly elevated, as it may require specific treatment beyond standard asthma management.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Bronchial asthma </span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute eosinophilic pneumonia </span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyper eosinophilic syndrome </span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary infiltrate with eosinophilia is seen in all of the following except?</span></p>",
      "unique_key": "DT1295750",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295750,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Pulmonary infiltrates with eosinophilia</strong> occur when eosinophils accumulate in the lungs due to various triggers like <strong>allergens, infections, or immune responses</strong>.</li>\r\n<li><strong>Bronchial asthma</strong> generally <strong>does not show pulmonary infiltrates</strong> on chest X-ray unless there is an associated complication like <strong>infection or allergic bronchopulmonary aspergillosis (ABPA)</strong>.</li>\r\n<li><strong>Primary pulmonary eosinophilic disorders</strong> such as <strong>acute eosinophilic pneumonia</strong> and <strong>Churg-Strauss syndrome</strong> present with characteristic infiltrates and eosinophilia.</li>\r\n<li>Conditions like <strong>hyper eosinophilic syndrome</strong>, <strong>drug reactions</strong>, and <strong>parasitic infections</strong> also cause eosinophilic infiltration in the lungs.</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> Bronchial asthma</strong>: Does not typically cause infiltrates unless complicated (e.g., infection or ABPA).</li>\r\n<li><strong> Acute eosinophilic pneumonia</strong>: Clear association with pulmonary infiltrates and high eosinophil counts.</li>\r\n<li><strong> Hyper eosinophilic syndrome</strong>: A systemic disorder causing eosinophilic infiltration in multiple organs, including the lungs.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Asthma alone usually does not present with pulmonary infiltrates</strong> unless infected.</li>\r\n<li><strong>Eosinophilic infiltrates</strong> are characteristic of disorders like <strong>eosinophilic pneumonia, Churg-Strauss, and certain infections</strong>.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 174,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute eosinophilic pneumonia </span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic eosinophilic pneumonia </span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypersensitivity pneumonitis </span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Eosinophilic granulomatosis with polyangiitis </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45 years old female presents with cough, progressive dyspnoea, weight loss and wheezing for last 6 months. Xray chest PA view shows photographic negative pulmonary oedema. What is the diagnosis?</span></p>",
      "unique_key": "DT1295751",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295751,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Chronic eosinophilic pneumonia</strong> presents with <strong>photographic negative pulmonary edema</strong> on chest X-ray, which is highly characteristic.</li>\r\n<li>Typically affects <strong>non-smoker females</strong> in the <strong>4th-5th decade</strong> with symptoms like <strong>progressive dyspnea, cough, weight loss, and wheezing</strong>.</li>\r\n<li>Rapid symptom improvement on <strong>corticosteroids</strong> is a hallmark.</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> Acute eosinophilic pneumonia</strong>: Presents acutely with severe respiratory distress and BAL eosinophilia &gt;25%, not with chronic symptoms or this X-ray finding.</li>\r\n<li><strong> Hypersensitivity pneumonitis</strong>: Usually caused by antigen exposure, presents with granulomatous inflammation, not photographic negative pulmonary edema.</li>\r\n<li><strong> Eosinophilic granulomatosis with polyangiitis</strong>: Often presents with systemic vasculitis and asthma, not typical photographic negative edema.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Photographic negative pulmonary edema</strong> is pathognomonic of <strong>chronic eosinophilic pneumonia</strong>.</li>\r\n<li><strong>Chronic eosinophilic pneumonia</strong> responds well to <strong>corticosteroids</strong> and commonly affects <strong>non-smoker females</strong>.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 182,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyper eosinophilic syndrome </span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute eosinophilic pneumonia </span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Eosinophilic granulomatosis with polyangiitis </span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Allergic bronchopulmonary aspergillus </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">50 years old male presents with adult onset asthma, peripheral eosinophilia, neuropathy and eosinophilic vasculitis. Investigation reveals High titer anti-Myeloperoxidase antibody positivity. What is the likely diagnosis?</span></p>",
      "unique_key": "DT1295752",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295752,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Eosinophilic granulomatosis with polyangiitis (EGPA)</strong> is characterized by <strong>adult-onset asthma, peripheral eosinophilia, neuropathy, and eosinophilic vasculitis</strong>.</li>\r\n<li>The presence of <strong>high titer anti-myeloperoxidase antibodies</strong> is a specific marker for EGPA, differentiating it from other eosinophilic conditions.</li>\r\n<li>Clinical features include <strong>asthma</strong>, <strong>sinusitis</strong>, <strong>pulmonary hemorrhage</strong>, and potential <strong>neuropathies</strong>.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010930437651-124b-4d31-94cb-be48000ba297.png\">\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> Hyper eosinophilic syndrome (HES)</strong>: Although it involves eosinophilia, it typically lacks the systemic vasculitis and anti-MPO positivity seen in EGPA.</li>\r\n<li><strong> Acute eosinophilic pneumonia</strong>: This condition presents acutely with respiratory distress, not chronic symptoms and vasculitis.</li>\r\n<li><strong> Allergic bronchopulmonary aspergillosis</strong>: Primarily causes asthma and eosinophilia but does not typically involve neuropathy or high anti-MPO antibodies.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>High titer anti-myeloperoxidase antibody positivity</strong> is indicative of <strong>Eosinophilic granulomatosis with polyangiitis (EGPA)</strong>.</li>\r\n<li>EGPA presents with <strong>asthma, peripheral eosinophilia</strong>, and <strong>neuropathy</strong>, highlighting its systemic nature.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 193,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">Glucocorticoid </span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">Mepolizumab </span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">Cyclophosphamide alone </span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">Imatinib</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the preferred 1st line therapy of Churg Strauss syndrome?</span></p>",
      "unique_key": "DT1295753",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295753,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Preferred First-Line Therapy</strong>:\r\n<ul>\r\n<li><strong>Glucocorticoids</strong> are the mainstay for <strong>Eosinophilic Granulomatosis with Polyangiitis (EGPA)</strong>, effectively reducing inflammation and managing symptoms.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Management Options</strong>:\r\n<ul>\r\n<li><strong>Cyclophosphamide</strong>: Used for <strong>severe cases</strong> or those unresponsive to glucocorticoids.</li>\r\n<li><strong>Rituximab</strong> and <strong>Azathioprine</strong>: Considered for <strong>refractory cases</strong>.</li>\r\n<li><strong>Mepolizumab</strong>: Anti-IL-5 therapy for eosinophilic inflammation but not first-line.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Key Clinical Features</strong>:\r\n<ul>\r\n<li>Focus on controlling eosinophilia and managing respiratory symptoms, as EGPA can have significant systemic involvement.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p>Management of EGPA and HES:</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501099a762d00-3ce1-46bf-8e81-68bad1cc5b75.png\">\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> Mepolizumab</strong>:\r\n<ul>\r\n<li>Not the primary treatment; adjunctive therapy for eosinophilic conditions.</li>\r\n</ul>\r\n</li>\r\n<li><strong> Cyclophosphamide alone</strong>:\r\n<ul>\r\n<li>Second-line option; may be used in refractory cases but not initial management.</li>\r\n</ul>\r\n</li>\r\n<li><strong> Imatinib</strong>:\r\n<ul>\r\n<li>Irrelevant to EGPA; used in different contexts (e.g., certain leukemias).</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Glucocorticoids</strong> are the <strong>first-line treatment</strong> for <strong>Churg-Strauss syndrome</strong>, providing rapid relief from symptoms.</li>\r\n<li><strong>Consideration of additional therapies</strong> depends on disease severity and response to glucocorticoids.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 201,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Peripheral eosinophilia </span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">IgE Antibody specific to aspergillus </span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Lower lobe bronchiectasis </span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">Very high serum IgE level >1000 IU/mL</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a feature of allergic bronchopulmonary aspergillosis?</span></p>",
      "unique_key": "DT1295754",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295754,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Allergic Bronchopulmonary Aspergillosis (ABPA)</strong>:\r\n<ul>\r\n<li><strong>Eosinophilia with Pulmonary Infiltrate</strong>: ABPA is characterized by <strong>eosinophilia</strong> due to hypersensitivity to <strong>Aspergillus</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Key Features</strong>:\r\n<ul>\r\n<li><strong>Peripheral Eosinophilia</strong>: Common in ABPA as part of the allergic response.</li>\r\n<li><strong>Specific IgE Antibodies</strong>: Presence of <strong>IgE</strong> and <strong>IgG</strong> antibodies specific to <strong>Aspergillus</strong> indicates the hypersensitivity.</li>\r\n<li><strong>Very High Serum IgE Levels</strong>: Levels &gt;1000 IU/mL are typical in ABPA.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Distinctive Finding</strong>:\r\n<ul>\r\n<li><strong>Lower Lobe Bronchiectasis</strong>: <strong>Not typical</strong>; ABPA primarily presents with <strong>central bronchiectasis</strong>, often affecting the upper lobes.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> Peripheral eosinophilia</strong>:\r\n<ul>\r\n<li>A hallmark of ABPA; confirms allergic response to Aspergillus.</li>\r\n</ul>\r\n</li>\r\n<li><strong> IgE Antibody specific to Aspergillus</strong>:\r\n<ul>\r\n<li>Crucial for diagnosis; indicates hypersensitivity.</li>\r\n</ul>\r\n</li>\r\n<li><strong> Very high serum IgE level &gt;1000 IU/mL</strong>:\r\n<ul>\r\n<li>Classic feature in ABPA; supports diagnosis of allergic response.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Central bronchiectasis</strong> is a defining feature of <strong>ABPA</strong>, while <strong>lower lobe bronchiectasis</strong> is <strong>not</strong></li>\r\n<li>Diagnosis relies on <strong>eosinophilia</strong>, <strong>specific IgE antibodies</strong>, and <strong>elevated serum IgE levels</strong>.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 213,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">Ascaris </span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Strongyloidiasis </span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Hookworm </span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">Schistosomiasis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All of the following organisms cause Loefflers syndrome except?</span></p>",
      "unique_key": "DT1295755",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295755,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Loeffler's Syndrome</strong>:\r\n<ul>\r\n<li>Defined by <strong>pulmonary infiltrate</strong> accompanied by <strong>peripheral eosinophilia</strong>.</li>\r\n<li><strong>Clinical Presentation</strong>: Includes <strong>cough</strong>, <strong>dyspnea</strong>, <strong>wheeze</strong>, and occasional <strong>hemoptysis</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Causes</strong>:\r\n<ul>\r\n<li><strong>Ascaris</strong>: Most common causative agent; larvae migrate through the lungs, leading to symptoms.</li>\r\n<li><strong>Hookworm</strong>: Also associated with Loeffler's syndrome through similar mechanisms.</li>\r\n<li><strong>Ancylostoma</strong>: Another organism contributing to this syndrome.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Not Associated</strong>:\r\n<ul>\r\n<li><strong>Strongyloidiasis</strong>:\r\n<ul>\r\n<li>Not a cause of Loeffler's syndrome; instead, it can lead to <strong>fatal hyperinfection syndrome</strong> in immunocompromised patients.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Other Options:</strong></p>\r\n<ul>\r\n<li><strong> Ascaris</strong>:\r\n<ul>\r\n<li>The primary organism responsible for Loeffler's syndrome; key player in causing pulmonary symptoms.</li>\r\n</ul>\r\n</li>\r\n<li><strong> Hookworm</strong>:\r\n<ul>\r\n<li>Known to cause Loeffler's syndrome through lung migration of larvae.</li>\r\n</ul>\r\n</li>\r\n<li><strong> Schistosomiasis</strong>:\r\n<ul>\r\n<li>While it can cause eosinophilia, it is not typically associated with the pulmonary features of Loeffler's syndrome.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Loeffler's syndrome</strong> is primarily linked to <strong>Ascaris</strong> and <strong>Hookworm</strong> infections, causing <strong>pulmonary infiltrates</strong> and <strong>eosinophilia</strong>.</li>\r\n<li><strong>Strongyloides</strong> does not cause this syndrome but poses a significant risk in immunocompromised individuals.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 222,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}